Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Chlorproguanil-dapsone-artesunate (CDA), artemether-lumefantrine, chlorproguanil-dapsone
Chlorproguanil-dapsone-artesunate · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| chlorproguanil-dapsone-artesunate | DRUG | - |
| artemether-lumefantrine | DRUG | - |
| chlorproguanil-dapsone | DRUG | - |
| Chlorproguanil-dapsone-artesunate (CDA) | DRUG | - |
Inclusion criteria: * Acute, uncomplicated P.falciparum malaria, microscopically confirmed * Temperature at screening of 37.5oC or or more or confirmed history of fever within previous 24 hours * Weigh 7.5kg or over * Screening haemoglobin (Hb) of 7g/dl or over, or haematocrit of 25% or more(If Hb ...
Chlorproguanil-dapsone-artesunate is an investigational combination therapy developed for the treatment of uncomplicated Plasmodium falciparum malaria. It combines three antimalarial agents in a single regimen. It is not approved and remains in clinical development. Studies enrolled adults and children, including children as young as 12 months, in African countries where falciparum malaria is endemic.
Chlorproguanil-dapsone-artesunate is developed by GSK plc, which trades under the ticker GSK. The company sponsored the clinical trial program evaluating the combination for uncomplicated falciparum malaria in Africa. The program includes studies conducted in Malawi, The Gambia, Burkina Faso, Ghana, Mali, Nigeria, Kenya, and Tanzania.
Chlorproguanil-dapsone-artesunate is in Phase 2 development. It is an investigational product and is not approved for any indication. The clinical program includes a Phase 2 trial and two Phase 3 trials, all of which are completed. No trials are currently active.
Chlorproguanil-dapsone-artesunate has been studied in three completed trials: NCT00519467, a Phase 2 safety and efficacy study of artesunate combined with LAPDAP in Malawi and The Gambia; NCT00371735, a Phase 3 comparison against chlorproguanil-dapsone (LAPDAP) in Burkina Faso, Ghana, Mali, and Nigeria; and NCT00344006, a Phase 3 comparison against COARTEM in Burkina Faso, Ghana, Kenya, Nigeria, and Tanzania.
Yes. Chlorproguanil-dapsone-artesunate is also known as CDA, an abbreviation formed from the three components of the combination. The same asset appears in the literature and in trial records under both the full name and the CDA abbreviation, including the Phase 3 trial NCT00371735, which is titled using the CDA name.
Across its completed clinical trials, chlorproguanil-dapsone-artesunate has been studied in approximately 2,295 participants. The Phase 2 trial NCT00519467 enrolled 120 participants, while the two Phase 3 trials, NCT00371735 and NCT00344006, enrolled 900 and 1,395 participants respectively. The trials were randomized and enrolled both adults and children.